Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Meridian Bioscience rallies on upgrade, positive analyst sentiment

Mon. July 21, 2008; Posted: 12:38 PM
Stocks RSS
SAN FRANCISCO, Jul 22, 2008 (Thomson Financial via COMTEX) -- VIVO | Quote | Chart | News | PowerRating -- Shares of Meridian Bioscience Inc. rallied Monday after Hilliard Lyons upgraded the stock to long-term buy from neutral and C.L. King & Associates reiterated its view that the stock remains "very strong."

Hilliard Lyons analyst Stephen O'Neil noted Monday that a recent drop in the stock price, which came after third-quarter revenue fell below analyst estimates, was partly due to lower than expected sales in the Cincinnati company's life sciences division.

But the key products at Meridian, which makes rapid diagnosis test kits for infectious diseases and licenses technology, continue to grow and Meridian will likely also benefit from new product launches, he wrote in a note to clients.

O'Neil estimates 2008 earnings of 74 cents a share and 2009 earnings of 90 cents a share. The mean estimate of analysts polled by Thomson Reuters were per-share profits of 73 cents in 2008 and 89 cents in 2009.

Meanwhile, at C.L. King analyst Ross Taylor on Monday lowered his 2009 per-share earnings view to 88 cents from 89 cents and his 2010 estimate to $1.03 from $1.05 because of the lower life sciences unit revenue.

Taylor reiterated his accumulate rating on the stock. The outlook for Meridian's diagnostic business, which contributes 80% of its revenue and 89% of income, remains "very strong," he wrote in a research note.

"We think the decline in the stock represents an attractive opportunity to buy the stock at a lower valuation," he said.

Meridian shares were up 4.6% at $25.08 in afternoon trading.

Brigid Gaffikin bg/vj

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

MMMM

For full details on Meridian Bioscience Inc (VIVO) click here. Meridian Bioscience Inc (VIVO) has Short Term PowerRatings of 5. Details on Meridian Bioscience Inc (VIVO) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.